Compare DexCom, Inc. (DXCM) vs Unity Software Inc (U) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Unity Software Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.81B), while Unity Software Inc trades at $46.21 (market cap $20.00B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Unity Software Inc is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Unity Software Inc for 50 Days on average.
| DXCM | U | |
|---|---|---|
Market Cap | $31.81B | $20.00B |
Volume | 2,861,821 | 12,798,386 |
Sector | Health | Technology |
52-Week High | $92.34 | $49.47 |
52-Week Low | $54.84 | $17.13 |
Typical Hold Time | 62 Days | 50 Days |
Enterprise Value | $31.26B | $19.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Unity Software (U) trades at $45.89, up 2.09% today, with strong technical momentum and bullish analyst sentiment. The stock shows improving fundamentals with revenue stabilizing around $1.8B-$2.0B and narrowing losses, though profitability remains negative. Recent catalysts include Meta VR Glasses support and positive sector momentum from Accenture's earnings. Technical indicators show the stock trading near resistance at $46 with overbought short-term RSI conditions.
Outlook remains cautiously optimistic with 82% analyst buy ratings and $45.27 consensus target. Key opportunities include VR/AR growth and advertising platform expansion, while risks center on persistent losses, high valuation multiples, and competitive pressures. The stock's current level near analyst targets suggests limited near-term upside without significant earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
